Compliance, Costs, And Site Readiness In CAR-T Clinical Trials

By Sachit Verma, MD, MBA, FACHE, FAPCR

Achieving sustained success in CAR-T clinical trials goes beyond simply managing daily operations. Clinical trial supply leaders must effectively navigate accreditation standards, regulatory requirements, budgeting, quality control, and site infrastructure to support trials efficiently. Expanding on the operational insights discussed in my previous article, these factors play a crucial role in ensuring sites are prepared, compliant, and capable of managing expenses while providing safe and timely patient care.

CAR-T clinical trials involve complex logistical, regulatory, and financial requirements that necessitate specialized site readiness, strict compliance, and significant – frequently underestimated – expenses. ¹ According to recent data, the total costs for commercially produced CAR-T products nearly reached $500,000, not including additional clinical expenses such as medications, hospital stays, and blood transfusions. ² Strict compliance with FDA regulations and Risk Evaluation and Mitigation Strategies (REMS) is crucial due to potential toxicities like CRS and neurotoxicity. This requires careful navigation through complex reimbursement and logistical hurdles.

1. Compliance And Accreditation

Compliance and accreditation guidelines are essential for ensuring the proper administration of complex, personalized therapies in CAR-T clinical trials. These guidelines serve as a critical link between research and clinical practice, guaranteeing patient safety and data accuracy. Research sites must strictly adhere to FDA regulations outlined in 21 CFR Part 312, including timely reporting of serious adverse events.

• Adherence to FACT/JACIE Standards: Sites are required to maintain accreditation (such as FACT in the U.S.) for the handling of cellular therapies. The extensive documentation needed to demonstrate compliant handling, from start to finish, poses a significant administrative burden on clinical staff.
• Chain of Custody (COC) Transfers: The transfer of cellular products between couriers and hospital pharmacies is a critical compliance point with high risk. Delays in the pharmacy staff checking in the shipment can lead to LN2 depletion or issues with the documentation trail.
• Site Onboarding: By choosing accredited sites for trial sponsors, the need for repetitive, thorough audits is minimized, as these sites have already proven the quality of their management infrastructure.
• Risk Evaluation and Mitigation Strategies (REMS): The recent FDA guidance on REMS for CAR-T development marks a significant change, emphasizing the need for randomized trials with standard-of-care control groups and a clear demonstration of superiority over existing therapies. Simultaneously, there is a reduction in REMS requirements to alleviate logistical burdens and enhance safety management strategies for treatment centers and patients. Effective June 2025, the FDA removed the mandatory REMS for approved BCMA- and CD19-directed autologous CAR T cell therapies. This move may indicate a broader trend toward the normalization of complex biologic treatments.³

2. Institutional Review Board (IRB) And Billing Processes

To maintain compliance with clinical trial billing regulations, it is essential for institutions to establish a clear connection between IRB protocol modifications and the financial management of trial materials and supplies. This connection helps prevent improper double-billing and ensures that costs are billed to the appropriate payer, whether it be the sponsor, a grant, or a third-party insurance provider. When modifications are made to an IRB protocol, it is crucial to update the financial structure to accurately reflect any changes in material requirements or supply responsibilities. This includes updating the study budget and Medicare Coverage Analysis (MCA) to account for any significant amendments, such as changes in dosing, new research objectives, or additional assessments. Specialized platforms like OnCore are often utilized to integrate the active IRB protocol with a specific study fund number, ensuring that financial updates are accurately reflected in the system. Additionally, any new fees incurred because of protocol amendments, such as those from the IRB itself, must be included in revised research budgets and invoiced to the sponsor accordingly.

• Complex Billing: Hospital billing departments face challenges in distinguishing between standard of care and trial-related logistics costs. Incorrectly billing a patient's insurance for a trial-sponsored shipment can lead to compliance audits and legal consequences.
• Protocol Creep: Should a sponsor decide to modify the logistics protocol, such as changing the frequency of temperature monitoring, the site will be required to manually update and re-approve their internal quality board for their local SOPs. This may lead to a temporary suspension in patient enrollment, commonly known as a blackout period.
• Process for Billing Trial Materials and Supplies: It is essential to have a well-documented billing process in line with the current IRB-approved study protocol to ensure accurate management of costs associated with supplies. Completion of the MCA is necessary before study activation can proceed. Any delays in conducting this analysis will result in corresponding delays in opening the logistics node for patient enrollment. In conducting a thorough MCA, it is imperative to review protocol documents to discern the classification of items/services as either routine care or research-only. Consistency in billing practices is paramount to comply with regulations, ensuring that the sponsorship covers expenses uniformly for all participants. Integration with electronic medical records (EMR) streamlines charge allocation based on IRB-associated protocols, enhancing accuracy and efficiency in billing processes.

3. Logistics Expenses In The Clinical Trial Agreement (CTA)

When negotiating logistics costs in a CTA for high-complexity therapies such as CAR-T, the challenge lies in transferring hidden operational risks and expenses from the hospital budget to the sponsor. Understanding the costs and fees linked to CAR-T therapy plays a vital role in the treatment process. Factors like staff accuracy, site readiness, and patient care impact these expenses. Paying close attention to each detail is key for seamless operations. Having sufficient supply levels is crucial for safety standards in CAR-T therapy. Forming a secure COC relies on having the right staff and proper training. Overlooking these factors could lead to major financial setbacks and delays in clinical trials. Prioritizing these aspects helps boost efficiency, elevate patient care, and increase the therapy's success rate.

A. Specialized Labor and Administrative Fees

• Cell Therapy Coordinator Fee: It is essential to include a separate line item for the administrative tasks related to managing conflicts of interest and confidentiality across multiple platforms.
• After-Hours Receiving Premium: Specify the reimbursement for pharmacy or lab staff who are required to receive cryogenic shipments outside of regular working hours.
• Training Reimbursement: Ensure coverage for the time spent by site staff on completing sponsor-specific logistics and handling certifications.

B. Infrastructure and Storage Costs

• Floor Space Fee: Negotiate a monthly storage fee for cryogenic dewars or specialized freezers that occupy valuable hospital space.
• Provision of Liquid Nitrogen (LN2): When utilizing site-owned dewars, the sponsor is responsible for covering the expenses associated with LN2 consumables and calibration of monitoring equipment.
• Maintenance of Equipment: Clarify the party responsible for funding the annual validation and servicing of site-based thawing devices or ultra-low freezers utilized exclusively for the trial.

C. Protection Against Logistics Failures

• Compensation for Failed Runs/Out-of-Spec (OOS) Products: Consider implementing a set fee or payment for any work completed when a product does not meet quality standards and cannot be utilized.
• Apheresis Cancellation Fee: Provide compensation for staff time and supplies in the event of a manufacturing slot cancellation by the sponsor with insufficient notice.

D. Provision of Consumables and Ancillary Supplies

• Apheresis Kits and Shipping Boxes: Ensure the provision or full reimbursement of specialized collection kits and validated shippers.
• Thawing Supplies: Allocate reimbursement for disposable bedside supplies (e.g., tubing, infusion sets, and media) not typically included in hospital inventory.

E. Patient-Focused Logistics

• Travel and Concierge Services: Allocate reimbursement for patient housing and local transportation if the patient needs to stay near the site during the 30-day post-infusion monitoring period.
• Emergency Transport: Ensure financial coverage for immediate medical transportation in the event a patient must be transferred from a satellite clinic to the main ICU due to unexpected circumstances such as CRS.

4. Post-Trial Management And Records​

• Long-term Archiving: Incorporate charges for the required 15-year preservation of records essential for cellular therapies.
• Disposition and removal of products: This includes covering costs for the appropriate disposal of biohazardous materials or coordinating the return of empty cryogenic shippers with sponsorship.

Proper post-trial management and record-keeping are vital to ensuring accountability and participant safety following the completion of a CAR-T clinical trial. These procedures are essential for tracking investigational products and having ethical standards beyond the trial period. Thorough documentation of continued access plans, inventory monitoring, safety surveillance, and reporting is crucial for managing post-trial supply responsibilities accurately. Each step is recorded to demonstrate compliance with regulations and facilitate a smooth transition for participants from investigational products to standard care. By implementing robust post-trial supply plans and maintaining comprehensive documentation, clinical trials stay in compliance with regulatory and ethical standards, ultimately placing patient well-being as a top priority.

Advanced Site Readiness And Infrastructure

Your vision for the site as a key logistics hub in the healthcare world sets you up for success. Site readiness is more than just a one-time event — it's about building a dependable, consistent factory within the hospital. Ensuring readiness involves evaluating the capacity of the apheresis suite; a shortage of chairs relative to waiting patients can disrupt the supply chain at the outset. Comprehensive training on labeling and scanning protocols for all nursing staff and technicians is vital in preventing manual errors that may lead to costly mistakes. A prepared site thrives on transparent communication between the clinical team and the supply chain, enabling prompt adjustments to unforeseen circumstances, such as patient infections, by quickly rescheduling manufacturing slots to prevent resource wastage.

Sites need more than a standard setup; it requires meeting strict regulatory and technical standards:

• Infrastructure Audit: Sites need reliable physical and operational setup, including cryogenic storage, apheresis slots, and backup power.
• Special Certification: Sponsors often demand FACT accreditation for international standards compliance.
• Data Systems: Having interoperable IT is crucial for data collection and monitoring in trials.
• Specialized Workforce and Team-Based Care
  • Cellular Advisory Teams (CAT): Some use dedicated CATs with CAR-T specialists to speed up trial processes.
  • Single Point of Contact (SPOC): Assigning a SPOC ensures smooth communication, avoiding delays.
  • Standardized Training: Regular training for staff is crucial for patient safety and trial consistency.
• Streamlining the Patient Journey and Access
  • Bridge Therapy Optimization: Sites need personalized strategies for patients with high tumor burden waiting for CAR-T.
  • Flexible Monitoring Models: Sites explore hybrid models for long-term monitoring, enabling patients to be closer to home.
  • Automated Scheduling: Electronic systems help manage capacity for apheresis slots and ICU beds, aligning manufacturing with patient readiness.
• Regulatory and Safety Coordination
  • Biosafety Committee (IBC) Alignment: Registering with the NIH and having active IBCs help sites avoid start-up delays in CAR-T trials.
  • Prophylactic Safety Measures: Using standardized risk-mitigation strategies like toxicity prediction can prevent adverse events and enhance trial safety.

5. Care Delivery Models

• Inpatient vs. Outpatient: The differences between inpatient and outpatient care delivery models for CAR-T cell therapy revolve around where patients are monitored post-infusion. While both models offer similar efficacy and safety, they come with distinct trade-offs in costs, resource utilization, and patient experience. The inpatient model involves a hospital stay for the infusion and initial monitoring, with 24/7 professional nursing and medical oversight and immediate access to acute care. On the other hand, the outpatient model allows infusion in a clinic or center and requires daily clinic visits for vital checks, providing patients with a higher quality of life and lower risk of hospital infections. Cost implications favor outpatient administration as more cost-effective for healthcare systems, albeit potentially shifting some financial responsibility to the patient.

Ensuring regulatory compliance, managing site costs, and optimizing site readiness are critical for CAR-T trial success. By strategically planning infrastructure, maintaining well-trained teams, and implementing robust quality control measures, clinical trial supply leaders can support sites effectively, reduce operational risks, and enable efficient patient care throughout the trial process.

Operational success in CAR-T trials at clinical sites relies on four essential pillars: stringent institutional readiness through FACT accreditation, strategic patient stabilization, workforce training, and efficient care delivery models, such as inpatient versus outpatient services. By prioritizing these critical aspects, we can effectively orchestrate well-tuned logistics that meet the complex needs of CAR-T therapies while maintaining a high level of operational efficiency and reliability. By strategizing around these pillars, supply leaders can optimize processes, mitigate risks, and ensure the smooth and compliant execution of CAR-T clinical trials, ultimately contributing to improved patient outcomes and advancements in healthcare innovation.

References:

1. Kamal-Bahl, S., Puckett, J. T., Bagchi, I., Miller-Sonet, E., & Huntington, S. F. (2022). Barriers and solutions to improve access for chimeric antigen receptor therapies. Immunotherapy. 10.2217/imt-2022-0037.
2. Shah, M., Krull, A., Odonnell, L., de Lima, M. J., & Bezerra, E. (2023). Promises and challenges of a decentralized CAR T-cell manufacturing model. Frontiers in transplantation, 2, 1238535.
3. FDA eliminates risk evaluation and mitigation strategies (REMS). (2025, June 26). U.S. Food and Drug Administration. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-eliminates-risk-evaluation-and-mitigation-strategies-rems-autologous-chimeric-antigen-receptor

About The Author:

Sachit Verma, MD, MBA, FACHE, FAPCR, is a board-certified healthcare leader with a diverse background in clinical research operations, administration, revenue cycle management, and compliance. Utilizing his expertise in clinical research, Dr. Verma has spearheaded systemwide initiatives to streamline trial delivery processes, uphold financial stewardship, and enhance operational efficiency by optimizing data analysis, budget management, and project life cycles. Dr. Verma possesses a diverse skill set in overseeing contracts, grants, feasibility assessments, study start-up initiatives, patient recruitment, enrollment and retention strategies, quality and performance improvement, and technology implementations.  Additionally, he is a successful author, speaker, mentor, and board member who combines leadership, regulatory knowledge, and best practices to ensure the success of projects and clinical operations.